AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04425148 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Alternating Current Stimulation (sham tACS)
Description: Sham (placebo) simulation of transcranial alternating current stimulation without receiving any real stimulation.
Study NCT03057132 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cavilon Advanced Skin Protectant
Description: Cavilon Advanced Skin Protectant
Study NCT01537250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500 mg placebol
Description: oral form,,once adily,7\~10 days
Study NCT01537250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nemonoxacin 3 tablets
Description: oral form,once daily,7\~10 days
Study NCT01538446 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modification of Prasugrel based on a biological assay
Description: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Study NCT01538446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prasugrel / clopidogrel
Description: fixed dose of prasugrel 5 mg
Study NCT01538446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Verify Now
Description: Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
Study NCT01364220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Rosuvastatin 20mg tablet, once daily, for 14 days
Study NCT01364220 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet, once daily, for 14 days
Study NCT03276702 — intervention group
Intervention type: PROCEDURE
Intervention: Re-biopsy
Description: For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
Study NCT03276702 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
Study NCT01950039 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Betaine
Description: Betaine or placebo administered orally in divided doses over 12 weeks
Study NCT02301234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
Study NCT02301234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 1 mg
Description: Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT02301234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulranumab 3 mg
Description: Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
Study NCT02301234 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Celecoxib 100 mg
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Study NCT02301234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib 100 mg Matching Placebo
Description: Double-blind capsules taken twice daily for up to 16 weeks.
Study NCT02911272 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-hour action line on WHO modified partograph
Description: observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
Study NCT02911272 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
Study NCT02911272 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
Study NCT01950039 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered orally in divided doses over 3 months
Study NCT06709599 — intervention group
Intervention type: OTHER
Intervention: Three-Week Strength and Conditioning Program
Description: Athletes train six days a week for three weeks, totaling approximately 15 hours of training per week. Training includes circuit training, weightlifting, technique drills, and sparring, designed to mimic typical MMA preparation.
Study NCT00683592 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT00680524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phone-based outreach
Description: Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
Study NCT05397301 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Controlled sedoanalgesia
Description: Controlled sedoanalgesia was applied with Bispectral index and dexmedetomidine
Study NCT01436448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probiotics Lactobacillus Rhamnosus
Description: Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
Study NCT04194151 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol Injection
Description: 1, 1.5 or 2 mg/kg of propofol according to the subgroup
Study NCT03968016 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: SYSMEX HLSCL
Description: Diagnostic device
Study NCT03968016 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SYSMEX HLSCL
Description: Diagnostic device
Study NCT04190927 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Compounded topical estradiol and compounded topical progesterone in a carrier cream
Description: Apply topical compounded estradiol and progesterone in the amount prescribed twice daily for each day of the 28 day lunar or menstrual cycle. Repeat each cycle month. Make note of any AE's so that modifications in dosing can be made.
Study NCT01280227 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SiSom
Description: SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
Study NCT02636673 — intervention group
Intervention type: PROCEDURE
Intervention: Sigmoid Resection
Study NCT05007639 — intervention group
Intervention type: OTHER
Intervention: Public Health intervention programme
Description: The public health intervention programme combined 3 actions : a simple dissemination of information via the regional Unions of private practice physicians and the local correspondents of the regional networks (action 1), an action in the form of oral communication during regional meetings of professionals (action 2) and an action focused on each surgeon for whom the pathologist has diagnosed soft tissue sarcoma (action 3).
Study NCT05007639 — intervention group
Intervention type: OTHER
Intervention: No public Health intervention programme
Study NCT00767208 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral glucose load
Description: oral ingestion of 13C labeled glucose
Study NCT05085847 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness meditation training
Description: Mindfulness-based intervention encompasses different practices which intend to exercise awareness by using mindfulness meditation training moment by moment. Thus, practices such as mindful breathing, compassionate communication, loving-kindness, self-compassion, mindful listening, dealing with difficulties, the 3 step meditation, walking meditation, body scan with progressive relaxation, thoughts, emotions, gratitude, and sounds and breathing will be teaching to participants. Mindfulness training will be conduct by two instructors with more than 30 years' experience in meditation practices (Zen and Tibetan Buddhist approach to mind-training) and extensive mindfulness teaching and practices (> 5 years each) experiences.
Study NCT05085847 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active control
Description: Participants will receive lectures that provide cognitive and sensorial stimulus which does not specifically involve awareness training (meditation). Lesson topics include science.
Study NCT00655317 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
Study NCT01648322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-627
Description: subcutaneous injection given 1 per chemotherapy.
Study NCT01648322 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neulasta® (pegfilgrastim)
Description: Single dose injection given once per chemotherapy cycle.
Study NCT01706315 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2140944
Description: GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
Study NCT01706315 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo will be available
Study NCT02408029 — intervention group
Intervention type: OTHER
Intervention: Observational study - no intervention
Study NCT04479852 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SP-624
Description: Oral capsule
Study NCT04479852 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral capsule
Study NCT03533569 — intervention group
Intervention type: PROCEDURE
Intervention: Intra-articular corticosteroid injection
Description: Participants with arthritis will undergo usual care with knee synovial fluid aspiration followed by intra-articular corticosteroid injection
Study NCT02510248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-704
Description: JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
Study NCT02510248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo to match AL-704
Study NCT01310751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iloprost nebuliser solusion
Description: 50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
Study NCT01310751 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: distilled water
Description: 2 ml per session
Study NCT04219904 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fludeoxyglucose F-18
Description: Given IV
Study NCT04219904 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol
Description: Given IV
Study NCT04219904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI
Study NCT04219904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI
Study NCT02911272 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Forewater amniotomy
Description: Forewater amniotomy at the vaginal examination confirming active phase labour
Study NCT03272230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ECOCAPTURE
Description: 45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
Study NCT03272230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive and Behavioral experimental tasks
Description: Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
Study NCT03272230 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Neuropsychological assessment
Description: STARKSTEIN APATHY SCALE (SAS) / DAS / MMSE / MADRS / EBI / MINI-SEA / FAB / HAD / MATTIS / HAYLING / STROOP / Verbal Span / Lexical verbal fluency / TMT / CDRS
Study NCT03272230 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ICM_APATHY_TASKS
Description: Apathy experimental task
Study NCT03272230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MRI
Description: T1 / T2 / rs-fMRI / MS-DWI
Study NCT03272230 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Neurohormonal mechanisms
Description: Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
Study NCT00655317 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
Study NCT01489930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Endurance exercise
Description: Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
Study NCT01489930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance exercise
Description: Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for \~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
Study NCT01489930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control/Combined training
Description: Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
Study NCT01516528 — intervention group
Intervention type: PROCEDURE
Intervention: Spirometry
Description: Assessment of lung function by spirometry
Study NCT02911272 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Forewater amniotomy
Description: Forewater amniotomy at the vaginal examination confirming active phase labour
Study NCT02911272 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 4-hour action line on WHO modified partograph
Description: observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
Study NCT03276364 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Point-of-care ultrasound examination by pulmonary and critical care fellow
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study NCT02710734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Administered Day 1 of each 14 day cycle for 3 cycles
Study NCT02823327 — intervention group
Intervention type: GENETIC
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02823327 — intervention group
Intervention type: OTHER
Intervention: Medical Chart Review
Description: Medical chart review is performed
Study NCT04403945 — intervention group
Intervention type: DEVICE
Intervention: Sidestream dark field(SDF) imagining
Description: SDF imaging consists of a hand-held device that illuminates a region by surrounding a central light guide with concentrically placed light emitting diodes,which thus provide SDF illumination.
Study NCT01137734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Adjustable Annuloplasty Ring with option to adjust off pump.
Description: Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty repair, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
Study NCT01137734 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)
Description: Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
Study NCT03169621 — intervention group
Intervention type: PROCEDURE
Intervention: Endometrial Biopsy and endometrial fluid collection
Description: On day 5 of the Hormonal Replacement Therapy (after 5 days of progesterone administration), the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.~The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE.
Study NCT03485027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: the rechallenge regimen
Description: XELOX regimen: Oxaliplatin 130mg/m2, intravenous, on day 1; Capecitabine 1000mg/m2, oral, twice daily, continuously for 14 days; ±bevacizumab 7.5mg/kg, intravenous, on day 1; repeating every 3 weeks. FOLFOX regimen: Oxaliplatin 85mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. FOLFIRI regimen: Irinotecan 180mg/m2 on day 1; Calcium folinate 400mg/m2 on day 1; 5-FU 400mg/m2 on day 1; 5-FU 2.4g/m2, continuous intravenous infusion for 46 hours; ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Irinotecan monotherapy regimen: Irinotecan 180mg/m2 on day 1, ± Bevacizumab 5mg/kg or ± Cetuximab 500mg/m2, repeating every 2 weeks. Raltitrexed contained regimen: Raltitrexed 3mg/m2 on day 1; ± Bevacizumab 7.5mg/kg, repeating every 3 weeks; Raltitrexed 2mg/m2 on day 1; ± Cetuximab 500mg/m2, repeating every 2 weeks.
Study NCT01402934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch solution (Voluven) infusion
Description: fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
Study NCT03614455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milademetan
Description: Milademetan 100 mg capsule for oral administration
Study NCT03614455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Milademetan
Description: Milademetan 100 mg capsule for oral administration
Study NCT03614455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Itraconazole
Description: Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)
Study NCT03614455 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Posaconazole
Description: Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)
Study NCT03171064 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance and Endurance Exercise
Description: Machine-based, 2x/week endurance and resistance training for 12 weeks
Study NCT02219009 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MIND1 System
Description: Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
Study NCT01510509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Titanium bare metal stent (Titan2®)
Description: Titan2®, Hexacath, Paris, France
Study NCT01510509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Everolimus Drug Eluting Stent (Xience-V®)
Description: Xience-V®, Abbott Vascular, Santa Clara, California, USA
Study NCT03988543 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Self-management
Description: Enhanced care (EC) approach aimed to engage participants actively, and to increase self-efficacy, in the monitoring and managing of their symptoms. After patients complete the current EHR-integrated symptom monitoring, they will receive web-based, patient-centered information to gain knowledge on cancer-related outcomes, improve self-management skills, improve communication skills, and empower them to improve motivation and self-management.